Publications

Detailed Information

Impact of Prostate Volume on the Efficacy of High-Power Potassium-Titanyl-Phosphate Photoselective Vaporization of the Prostate: A Retrospective, Short-Term Follow-Up Study on Evaluating Feasibility and Safety

DC Field Value Language
dc.contributor.authorKu, Ja Hyeon-
dc.contributor.authorKim, Soo Woong-
dc.contributor.authorPaick, Jae-Seung-
dc.date.accessioned2012-06-14T06:11:20Z-
dc.date.available2012-06-14T06:11:20Z-
dc.date.issued2010-11-01-
dc.identifier.citationYONSEI MEDICAL JOURNAL; Vol.51 6; 877-882ko_KR
dc.identifier.issn0513-5796-
dc.identifier.urihttps://hdl.handle.net/10371/77069-
dc.description.abstractPurpose: We determined the impact of prostate volume on the efficacy of the high-power (80 W) potassium-titanyl-phosphate (KTP) photoselective laser vaporization of the prostate in men with lower urinary tract symptoms (LUTS). Materials and Methods: Patients were stratified into 3 groups according to prostate volume: `<40 g` (n = 49) and `40-59 g` (n = 49) and 60 g` (n = 22). Median follow-up was 9 months (range 6 to 21). Results: No differences in age and follow-up duration were observed in the three groups. At baseline, no significant differences were noted in the three groups in terms of the International Prostate Symptom Score (IPSS) (21.4, 19.4 and 19.1; p = 0.412) as well as the maximum flow rate (Qmax) (10.2, 9.2, and 8.6 mL/s; p = 0.291) and post-void residual (PVR) (66.2, 80.4, and 71.5 mL; p = 0.856). The mean operative times were 30.9, 46.9, and 58.6 minutes (p < 0.001) and total median energy deliveries for each group were 62.3, 97.6, and 135.9 kJ, respectively (p < 0.001). No severe intraoperative complication was observed. At the last follow-up, these parameters improved significantly regardless of prostate volume, and the IPSS (11.1, 9.4, and 12.3; p = 0.286) as well as Qmax (15.9, 15.9, and 14.2 mL/s; p = 0.690) and PVR (33.7, 28.4, and 14.2 mL; p = 0.395) were not significantly different among the groups. Conclusion: Although a larger prostate requires more time and energy delivery, photoselective laser vaporization of the prostate is safe and efficacious for patients with LUTS regardless of prostate volume.ko_KR
dc.language.isoenko_KR
dc.publisherYONSEI UNIV COLLEGE MEDICINEko_KR
dc.subjectProstateko_KR
dc.subjectKTPko_KR
dc.subjectlaser surgeryko_KR
dc.subjectvaporizationko_KR
dc.subjectbenign prostatic hyperplasiako_KR
dc.titleImpact of Prostate Volume on the Efficacy of High-Power Potassium-Titanyl-Phosphate Photoselective Vaporization of the Prostate: A Retrospective, Short-Term Follow-Up Study on Evaluating Feasibility and Safetyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor구자현-
dc.contributor.AlternativeAuthor백재승-
dc.contributor.AlternativeAuthor김수웅-
dc.identifier.doi10.3349/ymj.2010.51.6.877-
dc.citation.journaltitleYONSEI MEDICAL JOURNAL-
dc.description.citedreferenceSpaliviero M, 2008, J ENDOUROL, V22, P2341, DOI 10.1089/end.2008.9708-
dc.description.citedreferenceRieken M, 2010, WORLD J UROL, V28, P53, DOI 10.1007/s00345-009-0504-z-
dc.description.citedreferenceNaspro R, 2009, EUR UROL, V55, P1345, DOI 10.1016/j.eururo.2009.03.070-
dc.description.citedreferenceLee R, 2008, J UROLOGY, V180, P1551, DOI 10.1016/j.juro.2008.06.002-
dc.description.citedreferenceDu CJ, 2008, J ENDOUROL, V22, P1031, DOI 10.1089/end.2007.0262-
dc.description.citedreferencePaick JS, 2007, J SEX MED, V4, P1701, DOI 10.1111/j.1743-6109.2007.00574.x-
dc.description.citedreferenceMonoski MA, 2006, UROLOGY, V68, P312, DOI 10.1016/j.urology.2006.02.020-
dc.description.citedreferenceBouchier-Hayes DM, 2006, J ENDOUROL, V20, P580-
dc.description.citedreferenceTe AE, 2006, BJU INT, V97, P1229, DOI 10.1111/j.1464-410X.2006.06197.x-
dc.description.citedreferenceKrambeck AE, 2010, J ENDOUROL, V24, P433, DOI 10.1089/end.2009.0147-
dc.description.citedreferenceFu WJ, 2006, ASIAN J ANDROL, V8, P367, DOI 10.1111/j.1745-7262.2006.00134.x-
dc.description.citedreferenceBarber NJ, 2006, UROLOGY, V67, P80, DOI 10.1016/j.urology.2005.07.028-
dc.description.citedreferenceBachmann A, 2005, EUR UROL, V48, P965, DOI 10.1016/j.eururo.2005.07.001-
dc.description.citedreferenceSandhu JS, 2005, J ENDOUROL, V19, P1196-
dc.description.citedreferenceSarica K, 2005, J ENDOUROL, V19, P1199-
dc.description.citedreferenceMalek RS, 2005, J UROLOGY, V174, P1344, DOI 10.1097/01.ju.0000173913.41401.67-
dc.description.citedreferenceVolkan T, 2005, EUR UROL, V48, P608, DOI 10.1016/j.eururo.2005.07.013-
dc.description.citedreferenceBachmann A, 2005, EUR UROL, V47, P798, DOI 10.1016/j.eururo.2005.02.003-
dc.description.citedreferenceKumar SM, 2005, J UROLOGY, V173, P511, DOI 10.1097/01.ju.0000150099.31289.d7-
dc.description.citedreferenceReich O, 2005, J UROLOGY, V173, P158, DOI 10.1097/01.ju.0000146631.14200.d4-
dc.description.citedreferenceSandhu JS, 2004, UROLOGY, V64, P1155-
dc.description.citedreferenceSulser T, 2004, J ENDOUROL, V18, P976-
dc.description.citedreferenceTe AE, 2004, J UROLOGY, V172, P1404, DOI 10.1097/01.ju.0000139541.68542.f6-
dc.description.citedreferenceReich O, 2004, J UROLOGY, V171, P2502, DOI 10.1097/01.ju.0000128803.04158.76-
dc.description.citedreferenceHai MA, 2003, J ENDOUROL, V17, P93-
dc.description.citedreferenceShingleton WB, 1999, UROLOGY, V54, P1017-
dc.description.citedreferenceShingleton WB, 1998, SCAND J UROL NEPHROL, V32, P266-
dc.description.citedreferenceKuntzman RS, 1997, UROLOGY, V49, P703-
dc.description.citedreferenceKuntzman RS, 1996, UROLOGY, V48, P575-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share